Your donation will make a difference:
Cystic Fibrosis Trust

Please Log in

Log in

Not a registered user? Register with us

This trial has been added to your watchlist.

Do you want to receive email notifications when the trial status changes?

No Yes

Unfollowing a trial will remove it from the watchlist and stop status change email notifications

Are you sure you want to unfollow this trial?

Yes, remove from watchlist



Therapeutic category
the type of treatment or therapy being studied. A therapy could range from a medication addressing a particular characteristic of CF to a device or activity e.g. exercise


Trial status

Open to recruitment

Participating Centres
the different stages involved in the development of a new medication. Phase I focuses on initial safety in people. Phase 2 evaluates safety, correct dose and early signs of whether the medication works. Phase 3 is the stage before medication licensing and looks at safety and medication effectiveness. Phase 4 evaluates longer term use of a medication after it has been licensed for use

Phase III

Full title

Randomized, Double-Blind, Phase 3B Trial to Evaluate the Safety and Efficacy of 2 Treatment Regimens of Aztreonam 75 mg Powder and Solvent for Nebulizer Solution / Aztreonam for Inhalation Solution (AZLI) in Pediatric Subjects with Cystic Fibrosis (CF) and New Onset Respiratory Tract Pseudomonas aeruginosa (PA) Infection/Colonization

The primary objective of this study is to evaluate the safety and efficacy of a 14-day course versus a 28-day course of aztreonam for inhalation solution (AZLI) in participants with new onset Pseudomonas aeruginosa respiratory tract infection.

Trial Reference Number


Trial type


Length of participation
the length of time a participant will take part in a trial, from the first to the last appointment

28 days

the name of the treatment or therapy being researched

AZLI Placebo

Last edited date

11 July 2019

CF sponsor

Gilead Sciences

CF sponsor type


Who can take part?

Top inclusion criteria
  • Forced expiratory volume in one second (FEV1) ≥ 80% predicted (for subjects ≥ 6 years of age who can reliably perform spirometry assessments).
  • Clinically stable with no evidence of acute significant respiratory symptoms that would require administration of IV antipseudomonal antibiotics, oxygen supplementation, or hospitalization.
  • Documented new onset of positive respiratory tract culture for PA within 30 days of screening defined as either first lifetime documented PA-positive culture, or PA recovered after at least a 2-year history of PA-negative respiratory cultures (at least 2 cultures per year)
Top exclusion criteria
  • Use of oral antipseudomonal antibiotics for a respiratory event within 30 days of study entry (screening visit).
  • Changes in bronchodilator, corticosteroid, dornase alfa, or hypertonic saline medications within 7 days prior to screening.
  • Use of IV or inhaled antipseudomonal antibiotics within 2 years of screening.

CF centres running this trial


Birmingham Children's Hospital


Steelhouse Lane Birmingham West Midlands B4 6NH

Recruitment starts

February 2018

Recruitment ends

December 2019


Nagakumar, Prasad

Get in touch


Leicester Royal Infirmary


Infirmary Square Leicester Leicestershire LE1 5WW

Recruitment starts

January 2018

Recruitment ends

November 2019


Gaillard, Erol

Get in touch


Royal Devon and Exeter Hospital NHS Foundation Trust


Royal Devon and Exeter Hospital, Barrack Road, Exeter, Devon EX2 5DW

Recruitment starts

January 2018

Recruitment ends

October 2019


Oades, Patrick

Get in touch


Aberdeen Royal Infirmary


Foresterhill, Aberdeen AB25 2ZN



Get in touch
Show all participating centres